


Remarks

Claims 1-15 are pending in the application. Applicant respectfully traverses Examiner's restriction requirement in part. In compliance with the restriction request, Applicant elects the Group I claims. Consequently, Applicant has cancelled subject matter of Groups II, III, V, VI, VII, VIII and IX without waiver or prejudice and without admission of anticipation or obviousness. Applicants reserve the right to file divisional applications to capture the cancelled restricted subject matter.

Applicant provisionally elects the following specie from Example 74 in the specification having the following structure



and chemical name, 3-(8-Methoxy-3-phenethyl-3-aza-bicyclo[3.2.1]oct-8-yl)-benzamide, as the elected specie upon which the Examiner can initiate the examination of the elected claims. The provisionally elected specie falls within the scope of all pending claims as amended by this amendment. The specie is specifically claimed in Claim 10.

Applicants respectfully disagree with Examiner's restriction with respect to Group IV claims. Claims 11 and 12 are directly linked to the compounds of amended Claim 1; therefore, there would be no added burden on the Examiner to consider the pending composition and method of use claims along with the compounds of Claim 1. Even though the method of use claims may be independent and distinct, these claims would be subject to rejoinder when the compounds of Claim 1 are found allowable. (see, MPEP 821.04).


Claim 1 has been amended to correspond to the restriction requirement by removing the non-elected groups where AR is other than aryl and Q is a ring.

Claims 9 and 13-15 have been cancelled as being directed to non-elected subject matter.

Claim 10 has been amended to provide proper Markush language and to remove redundant compounds. In addition, 3-{3-[3-(1-Hydroxy-cyclohexyl)-propyl]-8-methoxy-3-aza-[3.2.1]oct-8-yl}-phenol was corrected to read as "3-{3-[3-(1-Hydroxy-cyclohexyl)-propyl]-8-methoxy-3-aza-bicyclo[3.2.1]oct-8-yl}-phenol." The name was missing bicyclo before [3.2.1], which is an obvious error.

Respectfully Submitted:

Date: November 7, 2006


Arlene K. Musser
Attorney for Applicants
Registration No. 37,895

Pfizer Inc.
Patent Department, MS 8260-1611
Eastern Point Road
Groton, Connecticut 06340
(860) 715-0871